title: Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT).
abstract: OBJECTIVE
  To assess the clinical results in terms of local control, toxicity, failure pattern and toxicity of SBRT in oligometastatic patients with inoperable lung metastases.
  
  
  METHODS
  Forty-four patients were treated (53 metastases). Dose regimen: 5 × 12 Gy (66 %), 8 × 7.5 Gy (20.8 %) and 10 × 5 Gy (13.2 %). Response was assessed using PET/CT at 6 months after SBRT.
  
  
  RESULTS
  Local control at 1 and 2 years was 86.7 %. Seventy-five percent of local failures had received a BED <105 Gy. After a median follow-up of 13.3 months, 25 % experienced distant progression. Overall survival at 1 and 2 years was 86.7 and 60.4 %, and cancer-specific survival was 95.3 and 75.2 %, respectively. Grade 2 toxicity was 6.8 %. There was no grade 3-4 toxicity.
  
  
  CONCLUSIONS
  SBRT is effective and safe. The main failure pattern is distant progression. The selection of patients with a high probability of remaining oligometastatic is crucial for the efficiency of SBRT, both clinically and in terms of resources.
authors.affiliation: Department of Radiation Oncology, Reina Sofía University Hospital, Avda. Menéndez Pidal, s/n, 14004, Córdoba, Spain, songar1@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: García-Cabezas
authors.forename: C
authors.initials: C
authors.lastname: Bueno
authors.forename: E
authors.initials: E
authors.lastname: Rivin
authors.forename: J M
authors.initials: JM
authors.lastname: Roldán
authors.forename: A
authors.initials: A
authors.lastname: Palacios-Eito
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011379:Prognosis; D016634:Radiosurgery / Q000401:mortality*; D012189:Retrospective Studies; D015996:Survival Rate